Clinical trials: Weight, Body
Overweight or Obesity
Extension Study of the Phase 3 Clinical Study of GZR18 Injection for Weight Loss
This is a Phase 3 extension study conducted in subjects who have received GZR18 Injection once every 2 weeks (Q2W) for weight loss treatment for 52 weeks, aiming to explore the effect and safety of continuous injection of GZR18…
- Trial name
- GZR18-BWM-303 (NCT07292441)
- Testing
- GZR18 injection
- Where
- 2 sites in China
- Volunteers
- 500 people
- Sponsor
- Gan & Lee Pharmaceuticals.
Obesity
Crave Crush Neuroimaging Study
The purpose of the research is to test whether a gymnemic acids (GA) lozenge will reduce reward region response to intake of high-sugar food and ad lib candy intake and whether the GA lozenge reduced reward region response to…
- Trial name
- NCT02949102
- Testing
- Crave Crush
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Oregon Research Behavioral Intervention Strategies, Inc.
Metabolism and Nutrition Disorder, Obesity
Investigate Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-0530 Alone and in Combination With Liraglutide in Overweight to Obese But Otherwise Healthy Male Subjects
This trial is conducted in the United States of America (USA). The aim of the trial is to investigate safety, tolerability and pharmacokinetics (the exposure of the trial drug in the body) for single doses of NNC9204-0530 alone…
- Trial name
- NCT02235961
- Testing
- NNC9204-0530, liraglutide
- Where
- United States
- Volunteers
- 163 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Schizoaffective Disorder, Schizophrenia
A Study Comparing Three Strategies to Switch Patients With Schizophrenia or Schizoaffective Disorder to Risperidone After Unsuccessful Treatment With Olanzapine.
The purpose of this study is to compare three strategies for switching patients with schizophrenia or schizoaffective disorder to the atypical antipsychotic, risperdone, after they have been unsuccessfully treated with another…
- Trial name
- NCT00378183
- Testing
- risperidone
- Volunteers
- 120 people
- Sponsor
- Janssen, LP
Obesity, Overweight
Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
Obesity is a condition where a person has excessive body fat, defined by a body mass index (BMI) of 30 kg/m2 or higher. The goal of this study is to evaluate the effect of various doses of ABBV-295 compared to placebo on reducing…
- Trial name
- NCT07752979
- Testing
- ABBV-295
- Where
- 64 sites in United States, Puerto Rico
- Volunteers
- 360 people
- Sponsor
- AbbVie
Growth, Neonates
Improving Artificial Intelligence-derived Algorithms for Estimating Length and Weight in NEonateS and infanTs up to 6 Months of Age (NEST)
The NEST study is a prospective, observational research study designed to collect clinical measurements and image data to develop and evaluate artificial intelligence (AI)-derived algorithms for estimating anthropometric…
- Conditions
- Growth, Neonates, AI (Artificial Intelligence)
- Trial name
- NEST (NCT07514182)
- Where
- Singapore
- Volunteers
- 60 people
- Sponsor
- Danone Asia Pacific Holdings Pte, Ltd.
Diabetes Mellitus, Type 2, Diabetes Mellitus
A Study of the Safety and Effectiveness of a R256918 in Patients With Type 2 Diabetes
The purpose of this study is to investigate the effectiveness and safety of 12 weeks of treatment with R256918 in patients with Type 2 Diabetes Mellitus who are taking metformin.
- Conditions
- Diabetes Mellitus, Type 2, Diabetes Mellitus, Endocrine System Diseases, Nutritional and Metabolic Diseases
- Trial name
- NCT00672386
- Testing
- JNJ16269110, Metformin, Dietary Counseling
- Where
- 62 sites in Belgium, Denmark and 9 more
- Volunteers
- 352 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Obesity & Overweight
Safety, Tolerability and Pharmacokinetics of a Subcutaneous Semaglutide Implant
The study will evaluate the safety, tolerability and drug levels of a semaglutide implant placed just under the skin for a period of 4 weeks compared to 4 weekly injections of semaglutide (Wegovy) in overweight/obese participants…
- Trial name
- SLIM-1 (NCT07430059)
- Testing
- Semaglutide Implant (NPM-139), Semaglutide (Wegovy) weekly injection
- Volunteers
- 20 people
- Sponsor
- Vivani Medical, Inc
Obesity, Overweight
A Study of Eloralintide (LY3841136) in Chinese Participants With Obesity or Overweight
The purpose of this study is to evaluate how well Eloralintide (LY3841136) is tolerated and what side effects may occur in overweight and obese Chinese participants.
- Trial name
- NCT06916091
- Testing
- Eloralintide
- Where
- Singapore
- Volunteers
- 30 people
- Sponsor
- Eli Lilly and Company
Obesity
Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs Placebo
This is a proof-of-concept study to assess the safety and efficacy of Nimacimab Injection compared to an active and placebo injection control.
- Trial name
- CBeyond (NCT06577090)
- Testing
- Nimacimab injection, semaglutide injection, Nimacimab 300 mg injection
- Where
- 16 sites in United States
- Volunteers
- 136 people
- Sponsor
- Skye Bioscience, Inc.
Obesity
Safety, Tolerability and Pharmacokinetics of Multiple Doses of ZGN-433 in Obese Female Volunteers
The purpose of this study is to assess whether multiple doses of ZGN-433 is safe and well tolerated in obese female subjects. The study will also provide information on how much ZGN-433 gets into the blood, how long does it stay…
- Trial name
- NCT01028261
- Testing
- ZGN-433
- Where
- 2 sites in Australia
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Zafgen, Inc.
Obesity
Gastric Electrical Stimulation (GES) for the Treatment of Obesity
The purpose of this feasibility study is to provide safety data on the implantable Exilis gastric electrical stimulation (GES) system, to individually adjust stimulation parameters to levels that are comfortable for implanted…
- Trial name
- GES (NCT01823705)
- Testing
- Exilis Implantable Gastric Electrical Stimulation (GES)
- Where
- 4 sites in United States, Netherlands
- Volunteers
- 32 people
- Sponsor
- Medtronic Corporate Technologies and New Ventures
Obstructive Sleep Apnea, Obesity
Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea
The purpose of this study is to evaluate the effect and safety of tirzepatide in participants with moderate to severe obstructive sleep apnea and obesity who are both unwilling or unable to use Positive Airway Pressure (PAP)…
- Trial name
- SURMOUNT-OSA (NCT05412004)
- Testing
- Tirzepatide
- Where
- 58 sites in United States, Australia and 8 more
- Volunteers
- 469 people
- Sponsor
- Eli Lilly and Company
Hypertension
Testing the Efficacy of Different Dosages of Lercanidipine to Reduce Hypertensive Blood Pressure in Normal Weight and Obese Patients
A double blind study to examine the safety and efficacy of different dosages of lercanidipine in normal weight and obese patients with hypertension
- Trial name
- NCT00160498
- Testing
- Lercanidipine
- Volunteers
- 180 people
- Sponsor
- UCB Pharma
Schizophrenia
Control of Metabolic and Cardiovascular Risk in Patients With Schizophrenia and Overweight
To analyse the progress of modifiable metabolic risk factors (Blood pressure, cigarette smoking, waist perimeter, BMI, glycemia and lipidic profile) in schizophrenic patients with overweight for 12 months.
- Trial name
- CRESSOB (NCT00584519)
- Testing
- non-interventional
- Volunteers
- 430 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Functional Gastrointestinal Disorders (FGIDs), Weight Loss
Effects of Multi-strain Bacillus Spore Probiotics on Growth, Digestive Function, and Gut Microbiota in Cesarean-Delivered Neonates
Infants born by cesarean section commonly show early weight loss and slower recovery of birth weight, together with characteristic patterns of gut microbiota dysbiosis marked by reduced Bifidobacterium and Bacteroides and…
- Trial name
- NCT07320287
- Testing
- RO water, LiveSpo PREG-MOM, LiveSpo CONSY
- Where
- Vietnam
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Anabio R&D
Pharmacology, Clinical
Study on the Safety of Neladenoson Bialanate, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Dug Given as a Single Oral Dose of 10 mg Immediate Release Tablet in Participants With Renal Impairment and Healthy Participants Matched for Age-, Gender-, and Weight
Neladenoson bialanate is currently under clinical development for a condition in which the heart has trouble pumping blood through the body (chronic heart failure).
- Trial name
- NCT04320771
- Testing
- Neladenoson bialanate (BAY 1067197)
- Where
- 2 sites in Germany
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Bayer
Gastrointestinal, Overweight , Obesity
A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Impact of CLB101TM️ on Gut Health in Healthy, Overweight Individuals
Anaerostipes caccae CLB101TM️ is a next-generation probiotic isolated from healthy humans. It was shown to be in decreased abundance in people with protein-based food sensitivities/allergies.
- Trial name
- NCT07336615
- Testing
- CLB101™️
- Where
- United States
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- ClostraBio Inc.
Insulin Resistance, Obesity
Pilot Study of GLY-LOW Supplementation in Postmenopausal Women With Obesity
A combination of generally regarded as safe (GRAS) compounds named GLY-LOW, which included: alpha lipoic acid, pyridoxamine, nicotinamide, piperine and thiamine, were examined in pre-clinical experiments.
- Conditions
- Insulin Resistance, Obesity, Cardiovascular Diseases, Cognitive Impairment
- Trial name
- NCT06242535
- Testing
- GLY-LOW
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Hoskinson Health and Wellness Clinic
Obesity
A Research Study to See How Semaglutide Helps People With Excess Weight, Lose Weight (STEP UP)
This study will look at how much weight participants will lose from the start to the end of the study. The weight loss in participants taking the investigational high dose of semaglutide will be compared to the weight loss in…
- Trial name
- STEP UP (NCT05646706)
- Testing
- Semaglutide
- Where
- 107 sites in United States, Bulgaria and 10 more
- Volunteers
- 1,407 people
- Sponsor
- Novo Nordisk A/S